| Aim | To investigate the feasibility of locomotor training with the HAL in chronic stroke patients and to examine differences between two functional ambulation subgroups | To evaluate the effects of the HAL suit on the gait of stroke patients undergoing rehabilitation | To explore the safety and feasibility of the HAL system when used for early onset, intensive gait training as part of an inpatient rehabilitation program for patients with hemiparetic stroke | To investigate the feasibility and safety of the HAL suit in the rehabilitation of patients in the acute phase after stroke | To examine the effects of gait rehabilitation using the HAL for patients in the recovery phase of stroke to test the feasibility of intervention and outcome assessment protocols for a future randomized controlled trial on a larger scale | To evaluate the possibilities of exoskeletal locomotor training with HAL under voluntary control and identify beneficial effects on functional mobility of the patients Hypothesis: that exoskeleton treadmill training is feasible and safe in application and capable of improving ambulatory mobility in chronic SCI patients | To investigate the feasibility of 16-session (8 week) HAL rehabilitation training for patients with limited mobility |
| Study design and setting | Single group study Out-patient setting | Single group study Inpatient rehabilitation setting | Single group study Inpatient rehabilitation setting | Single group study Inpatient rehabilitation setting | Randomized controlled study (outcome assessment not blinded) Inpatient rehabilitation setting | Single group study Out-patient setting | Single group study Out-patient setting |
| Inclusion criteria | 1. Requirement of physical assistance or assistive devices for standing up sitting down, and/or walking; 2. Understanding study protocol and expressing voluntary consent 3. A body shape that could fit in the robotic suit HAL 4. Concurrent use of physical and occupational therapies | Not reported | 1. <7 weeks since stroke 2. Able to sit 5 min 3. Unable to walk due to paresis 4. Postural control to allow standing with assistance 5. Understand instructions 6. Express informed consent 7. Body size that fits HAL | 1. Hemiplegi or ataxia after stroke 2. Height >120 cm weight <100 kg 3. Glascow coma scale >9 4. Systolic BP 100–160 mmHg 5. Saturation > 90% 6. Heart rate between 40 and 120 beats/min 7. Body temperature <37.5°C | 1. Hemiparesis from unilateral ischemic/hemorrhagic stroke 2. Time since onset <6 months | 1. Traumatic SCI with cronic incomplete or complete paraplegia 2. Present motor functions of hip and knee extensor and flexor muscle groups | 1. Musculoskeletal disability affecting ambulation 2. Physical assistance or assistive devices in at least one of following daily activities: standing up, sitting down, and walking 3. Ability to understand study and to express consent 4. Body size that fit HAL 5. Ability to undergo usual physical and occupational therapies |
| Diagnosis and number of patients | Stroke Divided into two subgroups based on FAC-score FAC 2–3 (dependent ambulatory) FAC 4–5 (independent ambulatory) Included n = 16 Completed n = 16 | Stroke Patients were divided in 3 groups: 1. Assisted group 2. Handrail group 3. Quad cane group included n = 16 completed n = 16 | Stroke Included n = 8 Completed n = 8 | Stroke Included n = 22 Completed n = 16 | Stroke Included n = 32 Completed n = 22 (11 in each group) | SCI Included n = 8 Completed n = 8 | Stroke n = 12 SCI n = 8 Musculoskeletal diseases n = 4 Other diseases n = 14 Included n = 38 Completed n = 32 |
| Time since event/disease onset | Months, mean: 47.1 ± 37.6 Months, range: 13–132 | Days, mean: 52 Days, range: 29–116 | Days, range: 6–46 | Days, mean: Group 1: 12.7 ± 7.6 Group 2: 9.5 ± 2.4 (divided into two groups based on occurrence of orthostatic hypotension) | Days, mean: HAL group 58.9 ± 46.5 Control group 50.6 ± 33.8 | Months, mean: 97.2 ± 88.4 Years, range: 1–19 | Years, range: 1–54 |
| Age | Years, mean: 61 Years, range: 18–84 | Years, mean: 63 Years, range: 53–78 | Years, mean: 53 Years, range: 39–64 | Years, mean: 66.6 Years, range: ?-90 (min not reported) | Years, mean: HAL group 67 Control group 75.6 Years, range: not reported | Years, mean: 48 Years, range: 36–63 | Years, mean: 53.2 Years, range: 18–81 |
| Gender | Men n = 12 Women n = 4 | Men n = 9 Women n = 7 | Men n = 8 Women n = 0 | Men n = 7 Women n = 15 (included, completed not reported) | Men n = 11 Women n = 11 HAL group, men n = 7, women n = 4 Control group, men n = 4, women n = 7 | Men n = 6 Women n = 2 | Men n = 21 Women n = 11 |
| Intervention | HAL-training: with use of mobile suspension system and harness. Sit-to-stand and walking No of sessions: n = 16 Times/week: approximately n = 2 (individualized) Duration, weeks, mean: 10.8 ± 3.5 HAL version: double leg Training lasted 90 min/session HAL training was 20–30 min/session | HAL-training: walking (overground), stair climbing No of sessions: n = 1 Times/week: NA Duration: NA HAL version: double leg | HAL-training: with use of treadmill and body weight support No of sessions: median 16, range 6–31 Times/week: n = 5 Duration, weeks: approximately n = 3 (individualized) HAL version: double leg Training lasted 90 min/session, max 60 min (effective time) | HAL-training: not reported No of sessions, mean: 3.8 ± 3.1 Times/week: not reported Duration, days, mean: 12.1 ± 7 HAL version: double leg | HAL training: with use of mobile suspension system and harness if necessary HAL group: no of sessions: n = 12 Times/week: n = 3 Duration, weeks: n = 4 HAL version: single leg Control group receiving conventional training: no of sessions: n = 12 Times/week: n = 3 Duration, weeks: n = 4 Training lasted 20 min per session | HAL-training: with use of treadmill and body weight support. Included some regular physiotherapy No of sessions, mean: 51.75 ± 5.6 Times/week: n = 5 Duration, days: n = 90 HAL version: double leg Training lasted 90 min/session | HAL-training: with use of mobile suspension system and harness, or treadmill and body weight support No of sessions: n = 16 Times/week: n = 2 Duration, weeks: n = 8 HAL version: double leg Training lasted 90-min/session (including all). Net walking time was approximately 20 min |
| Assessments | 10m walk test* (walk speed, number of steps, cadence) Timed up and go Berg balance scale | 10m walk test (stride length, speed) Physiological cost index Assessed before, during, after HAL training and the next day | 10m walk test Timed up and go Berg balance scale Functional ambulation categories NIH stroke scale Fugl-Meyer-LE Clinical outcome variable scale Falls-efficacy scale Barthel index Functional independence measure EQ-5D | Orthostatic hypotension and several medical and functional variables were assessed | 10m walk test (Max walking speed) Timed up and go Functional ambulation categories* 6 min walk test Fugl-Meyer-LE Short physical performance battery Isometric muscle strength | 10m walk test (time, number of steps, assistance) Timed up and go 6 min walk test Walking index for SCI II (WISCI II) Lower extremity motor score Muscle volume ASIA impairment scale | 10m walk test* Timed up and go* Berg balance scale* |
| Results | Dependent ambulators: improvements in 10m walk test (speed, cadence and number of steps) and berg balance scale. statistically significant differences (p < 0.05) Independent ambulators: improvements in Berg Balance Scale. Statistically significant differences (p < 0.05) Whole group: improvements in 10m walk test and berg balance scale. Statistically significant differences (p < 0.05) Adverse events reported as: no training-related serious adverse events were observed | During HAL training physiological cost index (PCI) increased in n = 11 participants. PCI was associated with ability to ambulate (p < 0.05) Walking speed decreased during training in n = 12 participants. Speed was associated with ability to ambulate (p < 0.05) Stride length increased during training in n = 4 participants. Stride length was not associated with ability to ambulate (p-value not reported) Adverse events: not reported | Improvements in FAC, Fugl-Meyer-LE, 10m walk test, and berg balance scale Statistically significant differences: not reported Adverse events reported as: no serious adverse events occurred | Improved walking and torso posture n = 2 Standing with HAL n = 12 No change n = 2 Withdrew n = 6 Statistically significant differences (p < 0.05): not reported Adverse events reported as: orthostatic hypotension (n = 4) | HAL group: improvements in independent walking (FAC), walking speed, timed up and go, 6 min walk test and Fugl-Meyer LE. Statistically significant differences (p < 0.05) Control group: improvements in independent walking (FAC), short physical performance and timed Up and go. Statistically significant differences (p < 0.05) Between groups: improvements in independent walking (FAC) greater in HAL group. Statistically significant differences (p < 0.04) Adverse events reported as: no participants withdrew because of adverse effects | All patients improved in treadmill training with HAL. Mean walking speed and average walking time increased Improvements in 10m walk test (gait speed, number of steps), lower extremity motor score, timed up and go, 6 min walk test statistically significant differences (p < 0.05) Improvements in walking index for SCI II. No statistically significant differences (p < 0.05) Adverse events reported as: neither adverse nor severe adverse events occurred during the intervention | Improvements in gait speed, steps and cadence based on 10m walk test, (27 participants) Statistically significant differences (p < 0.05) Improvements according to timed up and go and berg balance scale. No statistically significant differences (p < 0.05) Adverse events reported as: no serious training-related adverse events |
| Quality according to SIGN criteria | (−) | (−) | (−) | (−) | (−) | (−) | (−) |